Provectus announced that the company has successfully developed and manufactured a second halogenated xanthene (HX), adding to its lead, clinical-stage, HX small molecule called rose bengal sodium (RBS). The molecular name of the newly synthesized HX is 4,5,6,7-tetrabromo-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenz- ofuran-1,9'-xanthen]-3-one. Provectus' intellectual property estate comprises an entire class of proprietary, related HX molecules that are proprietarily-synthesized using Quality-by-Design principles (QbD) under current Good Manufacturing Practice (cGMP) and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1943 USD | 0.00% | +8.67% | +102.40% |
1st Jan change | Capi. | |
---|---|---|
+102.40% | 81.51M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- PVCT Stock
- News Provectus Biopharmaceuticals, Inc.
- Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule